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ABSTRACT 
Introduction 
Medication-related clinical decision support (CDS) alerts have been shown to be effective at reducing 
adverse drug events (ADEs). However, these alerts are frequently overridden, with limited data linking 
these overrides to harm. Dose-range checking alerts are a type of CDS alert that could have a significant 
impact on morbidity and mortality, especially in the intensive care unit (ICU) setting.  
Methods 
We performed a single-center, prospective, observational study of adult ICUs from September 2016 to 
April 2017. Targeted overridden alerts were triggered when doses greater than or equal to 5% over the 
maximum dose were prescribed. The primary outcome was the appropriateness of the override 
determined by two independent reviewers, using pre-specified criteria formulated by a multidisciplinary 
group. Overrides which resulted in medication administration were then evaluated for ADEs by chart 
review.  
Results 
The override rate of high dose-range alerts in the ICU was 93.0% (total n=1525) during the study period. 
A total of 1418 overridden alerts from 755 unique patients were evaluated for appropriateness 
(appropriateness rate: 88.8%). The most common medication associated with high dose-range alerts was 
insulin regular infusion (n=262, 18.5%). The rates of ADEs for the appropriately and inappropriately 
overridden alerts per 100 overridden alerts were 1.3 and 5.0, respectively (p<0.001).  
Conclusions 
Overriding high dose-range CDS alerts was found to be common and often appropriate, suggesting that 
more intelligent dose-checking is needed. Some alerts were clearly inappropriately presented to the 
provider. Inappropriate overrides were associated with an increased risk of ADEs, compared to 
appropriately overridden alerts. 
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Key Points 
- Overrides of high dose-range alerts are common and often appropriately done 
- Harm from these overrides was rare, although inappropriately overridden alerts were more 
associated with harm 
- Increasing the positive predictive value of these alerts may reduce provider alert fatigue 
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1. INTRODUCTION 
Adverse drug events (ADEs) have been associated with an increase in patient length of hospital 
stay, and patient morbidity and mortality [1-3]. Medication-related clinical decision support (CDS) is a 
potential way to reduce the occurrence of ADEs [4,5]. Despite these studied benefits, CDS alerts are 
overridden frequently, sometimes inappropriately [6-9]. Override rates are variable across institutions and 
dependent on the type of alert evaluated.  
A patient population that is particularly susceptible to ADEs includes those in the intensive care 
unit (ICU), due to an increased number of high-risk medications, altered pharmacokinetics, and 
susceptible organ systems (e.g., organ failure) [10-11]. Research regarding CDS alert overrides in the ICU 
is limited but suggests that up to 90% of these alerts are overridden, often appropriately [8,9]. However, 
when CDS alerts are overridden inappropriately, there is up to a 6-fold increase in ADEs compared to 
appropriately overridden alerts [9]. However, studies evaluating the risk of inappropriate overrides 
focused on common types of CDS alerts (allergy, drug-drug interaction, geriatric, renal) but had limited 
characterization of dose-range alerts, which detect potential underdosing and overdosing of prescribed 
medications.  
More broadly, few data are available regarding the impact of dosing CDS [12-15]. In one study 
evaluating medication prescriptions, one in 40 prescriptions were identified as having a dosing error with 
significant potential for patient harm, as the dose exceeded the maximum daily dose approved by the 
Summary of Product Characteristics [13]. Data indicates that tailoring of CDS to consider patient-specific 
factors reduces the prescription of excessive doses of medications [14].  
Patients in the ICU tend to be especially ill and have an especially high risk of adverse drug 
events. Dosing of medications in the ICU is complex, and we evaluated the clinical significance of high 
dose-range CDS alerts, which identify doses prescribed over the maximum that are likely to cause patient 
harm. To do this, we performed a prospective study of the frequency and appropriateness of high dose-
range alerts in the ICU and evaluated the clinical consequences of those which were overridden. By 
assessing how often these alerts appear, how providers respond to them, and identifying the extent of 
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harm associated with these high dose-range CDS alert overrides, we hope to identify ways to improve the 
current CDS alert systems. 
2. METHODS 
We performed a prospective, observational study of high dose-range medication-related CDS 
alert overrides by all types of providers (anesthesiologist, fellow, nurse practitioner, physician, physician 
assistant, resident). Although these alerts are presented to other clinicians (e.g., pharmacists, nurses) this 
study only focuses on providers. Alert overrides were generated between September 2016 and April 2017 
for patients admitted to one of the following adult ICUs at Brigham and Women’s Hospital: two medical, 
two neurology, two surgical. Targeted alerts were triggered when doses greater than or equal to 5% over 
the maximum daily dose recommended by our medication knowledge base (First DataBank, South San 
Francisco, CA, USA) were prescribed, and any high dose of high-risk medications, as identified by the 
Institute for Safe Medication Practices [16]. This knowledge base was not tailored by our institution and 
is not ICU-specific . Dose-range alerts were dependent on the daily dose, which accounted for factors 
such as renal function and weight, and included single-dose and infusion dose alerts if the maximum daily 
dose was above the recommended daily threshold. This study was approved by the Partners HealthCare 
Institutional Review Board. 
2.1 Appropriateness Evaluation 
Criteria for appropriateness of overrides were created using a similar approach described in our 
previously published data; part of this process drew on both guidelines and clinical experience of a 
multidisciplinary group [9,17]. Criteria were specific for alert categories and modified until a consensus 
was reached for the criteria specific to each alert. Appropriateness was independently evaluated for all 
overridden alerts by two reviewers, one clinical pharmacist (AW) and one research assistant (CR). The 
inter-rater agreement for appropriateness was determined with a κ statistic. Disagreements were resolved 
by discussions between the two independent reviewers, with a third experienced reviewer consulted when 
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necessary. The κ for the criteria agreement of appropriateness was 0.87 (95% CI 0.85-0.90), with an 
actual agreement of 88.0%.  
2.2 ADE Evaluation 
We performed patient chart reviews for all patients whose high dose-range alerts were overridden 
to see if this resulted in them experiencing an ADE. We considered the time period from which the alert 
was overridden to the point at which the order was stopped. Adverse drug events evaluated in this study 
were specific to the overridden alert (e.g., digoxin alert  symptomatic bradycardia). Data relevant to an 
ADE, such as laboratory reports, medication orders and patient notes documented by nurses or providers, 
were abstracted and summarized by one reviewer. These data were then forwarded to two independent 
reviewers to determine the likelihood (no ADE, potential ADE, definite ADE) and severity of the ADE 
(significant, serious, life-threatening). These two reviewers were blinded as to whether the alert was 
appropriately overridden or not by the clinician. If consensus was not achieved, a third experienced 
reviewer was consulted. The κ for ADE determination was 0.83 (95% CI 0.80-0.86) indicating almost 
perfect agreement, with an actual agreement of 85%. Study personnel had undergone training based on 
guidance developed by the Center for Excellence for Patient Safety Research at Brigham and Women’s 
Hospital, which has been used in previous studies and previously described [17].  
2.3 Statistical Analysis 
 Descriptive statistics were used to summarize patient characteristics. Fisher’s exact test was used 
to compare the difference in rate of ADEs by override appropriateness. A p-value of <0.05 was 
considered significant. Statistical analysis was completed using R V.3.3.3 (R Core Team, Vienna, 
Austria). 
3. RESULTS 
The override rate of high dose-range alerts was 93.0% (total n=1525) during the study period. We 
identified a total of 1418 dose-range overridden alerts from 755 patients admitted to the ICUs during the 
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study period. Patient demographics are detailed in Table 1. Patients were generally middle-aged and 
emergently admitted to the hospital (i.e., non-scheduled admissions) as a medical admission. 
3.1 Medications Associated with Overrides 
A total of 139 medications resulted in the 1418 alerts. The five most overridden medications were 
insulin regular (n=262, 18.5%), glycopyrrolate (n=79, 5.6%), lorazepam (n=70, 4.9%), heparin (n=60, 
4.2%), and calcium gluconate (n=56, 3.9%). In grouping by medication class, insulin was associated with 
the most overrides (n=262, 18.5%), followed by antibiotics (n=175, 12.3%), and benzodiazepines (n=138, 
9.7%). There were 429 (30.3%) overrides that were associated with a continuous infusion of a 
medication. There were 15 overrides (1.1%) which were apparent computer entry errors (e.g., selecting 
dose by weight instead of straight dose, extra zero at end of dose) (n=8: vancomycin; n=2: phenytoin; 
n=1: acetaminophen, methylprednisolone, morphine, pentobarbital, sodium bicarbonate oral). Of all 
overrides, 325 (22.9%) were associated with an override reason. “Will monitor” was the most frequently 
used override reason (n=177, 55.4%), followed by “Benefit outweighs risk” (n=101, 31.1%), and “Patient 
tolerated before” (n=20, 6.2%). There were three overrides that had an override reason of “Inaccurate 
warning” (n=2: sodium bicarbonate bolus; n=1: cefazolin).  
3.2 Appropriateness of Overrides  
The appropriateness rate of overrides was 88.8% (appropriate: n=1259; inappropriate: n=159). 
The medications associated with more than 1% of alert overrides and their rates of appropriateness are 
detailed in Table 2.  
Of the continuous infusion overrides, the vast majority were appropriately overridden (n=426, 
99.3%). All of the “Inaccurate warning” overrides were appropriate overrides. There were 89 medications 
(64.0%) that were only associated with an appropriate override. These included the commonly used 
medications in the ICU of fentanyl (n=39), haloperidol (n=31), morphine (n=15), and epinephrine 
infusion (n=12). There were a total of 17 medications that were only associated with an inappropriate 
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override. The highest number of these overrides was 2 each for atovaquone, ceftazidime, ciprofloxacin, 
and olanzapine.  
3.3 Evaluation of ADEs 
A total of 791 appropriately overridden (62.9%) and 20 inappropriately overridden alerts (12.6%) 
resulted in medication administration to the patient. The rate of ADEs for the appropriately and 
inappropriately overridden alerts per 100 overridden alerts was 1.3 and 5.0, respectively (p<0.001). 
Appropriate overrides resulted in exclusively non-preventable ADEs. Details of all the ADEs (n=11) 
found in this study are discussed in Table 3, including the medication and dose ordered, appropriateness 
of override and the type and severity of the ADE. There was no patient mortality related to the ADEs 
identified in this study. 
4. DISCUSSION 
We evaluated the appropriateness of high dose-range CDS overrides and the ADEs associated with 
these overrides in the ICU. We found that a high proportion of overrides were overridden and most of 
these overrides were appropriate. However, inappropriate overrides were associated with a four-fold 
increased risk of ADEs, compared to appropriately overridden alerts. These data suggest that to improve 
safety, we need to both turn off more of the unnecessary warnings and also underscore the small number 
of truly important ones.  
Much of the published data on high dose-range CDS alerts are focused on the pediatric patient 
population, due to the complex parameters that need to be factored in routinely, especially age and weight 
[18-22]. Recommendations from this population include the combination of dose-rounding guidelines, in 
addition to incorporation of cognitive processes (i.e., human factors) into the creation of CDS alerts. 
Studies in adult patient populations follow the same recommendations, although with much more lenient 
dose recommendations [12-14]. One study created an algorithm for dose-range checking, which was then 
tested in their institution’s EHR and led to subsequent refinement of their algorithm [12]. They found 11 
factors that could be incorporated into CDS alerts to improve their performance such as differentiation by 
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dosage form (e.g., oral vs. intravenous), incorporation of therapy indication, and incorporation of age into 
dosing. A main recommendation that is consistent is to evaluate the dose-range CDS alerts that exist 
within an institution. 
 Some of the medications associated with overrides were surprising because of how commonly 
these medications are used in the ICU. A small proportion of the alerts (1.1%) were apparently obvious 
deviations from standard dosing, occurring likely due to computer input key error. One example is for the 
ordering of vancomycin at our institution, which can be dosed by the provider for the final dose, or 
calculated by the computer by providing a dose by patient weight. This differs by how the vancomycin is 
ordered (i.e., stand-alone or via order set), leading to potential confusion dependent on what the provider 
might be used to. Standardization could help to prevent these errors from occurring. Many overrides were 
due to continuous infusions that actually followed our institutional guidelines, which illustrates one area 
for improvement in the decision support. The appropriateness rate of overrides is consistent with 
published literature [8,9,23]. The most significant findings in our appropriateness evaluation was that 89 
medications (64.0%) and their associated CDS alerts were exclusively appropriately overridden. Primary 
efforts to improve CDS alerts should target these medications to improve the clinical significance of high 
dose-range CDS alerts. 
 In the ADE evaluation, we found a significant increase in ADEs as a consequence of 
inappropriately overridden alerts, compared to appropriately overridden alerts. An interesting finding was 
the difference in the rate of medication administration by the appropriateness of the override, with 
appropriately overridden alerts approximately 5-times more likely to be administered to the patient. This 
may be due to identifying dose errors after initial prescription of the medication (e.g., pharmacist 
verification, nursing administration, subsequent provider discontinuation). These potential interventions 
may have contributed to the small number of ADEs (n=1) that we found in the inappropriately overridden 
alerts. Additionally, there were five ADEs that were a result of continuation of a patient’s home 
medication. Standard of care at our institution is to determine a patient’s home medication list within days 
of a patient’s admission; however, whether it is truly accurate or not is unknown as often ICU patients 
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may not be able to verbally provide correct information. Adverse events may have occurred due to the 
alterations in organ function related to critical illness [10,11]. These events are concerning as they are 
difficult to account for with dose-range alerts, as long as the patient was not admitted for a reason related 
to their home medications. 
4.1 Recommendations to Improve Clinical Decision Support 
Based on the findings of our study, one method to improve our institution’s high dose-range CDS 
alerts are to remove the alerts that coincide with our institutional dose guidelines, namely for continuous 
infusion medications. As shown by our results, all but three continuous infusion alerts were overridden 
appropriately according to institutional guidelines. Removal of these alerts, which accounted for 
approximately one-third of alerts during our study period would significantly reduce the number of alerts 
that providers may encounter.  
An additional method that has been shown to be successful is to use a statistical analysis approach 
to define sensible dosing limits [24]. They identified the 100 most commonly prescribed drugs at their 
institution and used two physicians to create theoretical ‘warning’ (highest single dose that would be 
reasonably prescribed) and ‘disallow’ (maximum dose allowable in any circumstance) limits. These limits 
were then compared to the prescriptions within their institution over a one-year period. They found an 
area under the curve for their predictive model of 99.4% and 99.7% for the ‘warning’ and ‘disallow’ 
limits, respectively.  
Continually monitoring alerts that have been identified by providers as clinically irrelevant (e.g., 
“Inaccurate warning”) is another potential method to improve CDS [25]. We found that the three alerts 
that were overridden with this reason were appropriately overridden. Acknowledging these overrides and 
educating providers that this a way to tailor an institution’s CDS alerts may help to increase buy-in of this 
technology to improve patient care.  
Finally, incorporation of additional patient factors will help to increase the positive predictive 
value of these alerts [13,14,26]. One approach includes the adaptation of a pharmacokinetic approach to 
dosing for patients with renal impairment due to the flaws associated with current systems [14]. In 
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addition, this study incorporated patient information (e.g., patient age, other ordered medications) from 
the EHR into dose recommendations. This improved algorithm resulted in a 20% decrease in excessive 
ordered doses compared to the baseline CDS (p<0.001). Other potential patient factors that can be 
included into these alerts are the degree of monitoring the patient has, the ordered monitoring that is 
available, and a patient’s past exposure to drugs and the associated doses with each episode.  
In summary, we believe that alerts in general should account for as many possible patient and 
institution characteristics as possible. This would include factoring in patient labs (e.g., electrolytes), renal 
function/replacement therapies, and institutional guidelines. Therefore, the “out-of-the-box” approach for 
commercial EHRs should be carefully evaluated at each institution to ensure that alerts are not 
overwhelming to front-line clinicians.   
4.2 Limitations 
Our study had several limitations. First, this study based on only one commercial EHR/database 
and therefore, may not necessarily be applicable to other institutions. This included accounting for factors 
such as renal function, which may not be included at other institutions. Second, we may not have factored 
in all possible aspects of why a provider may have overrode an alert. However, we believe that we made 
considerable efforts to include as many different aspects in determining appropriateness criteria, including 
the formulation of criteria using a multidisciplinary expert team and the independent adjudicators. Finally, 
we were dependent on clinical documentation for the determination of ADEs, which might have limited 
our findings. The small number of inappropriate overrides makes it difficult to compare the rate of ADEs 
between the appropriately and inappropriately overridden alerts. However, our results are consistent with 
research our study team has previously completed. 
5. CONCLUSION  
Approximately nine out of 10 identified dose-range CDS overrides were appropriately 
overridden. Inappropriate overrides were four times as likely to be associated with an ADE compared to 
appropriate overrides, confirming that decision support can identify clinically important situations and 
suggesting that better approaches are needed to make it clear to clinicians which decision support is 
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particularly important. Further efforts should be targeted at improving the positive predictive value of 
CDS in a number of ways, including the incorporation of more patient-specific factors. 
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TABLES 
Table 1. Patient demographics (n=755) 
Mean age, y (SD) 60.3 (17.5) 
Male, n (%) 378 (50.0) 
Emergent admission to hospital, n (%) 670 (88.7) 
Hospital admission type, n (%) 
 Medical 469 (62.1) 
 Surgical 286 (37.9) 
ICU admission type, n (%) 
 Medical 500 (66.2) 
 Surgical 255 (33.8) 
Initial ICU admitted to, n (%) 
 Medical 333 (44.1) 
 Neurology 193 (25.6) 
 Surgical 229 (30.3) 
Median SOFA, (IQR) 4 (2, 6) 
Median ICU LOS, d (IQR) 6.6 (3.1, 12.2) 
Median hospital LOS, d (IQR) 14.5 (8.2, 23.8) 
Deceased, n (%) 182 (22.1) 
ICU = intensive care unit; LOS = length of stay; SD = standard deviation; SOFA = Sequential Organ Failure Assessment  
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Table 2. Medications accounting for >1% of total sample and rate of appropriateness 
Medication Inappropriate override, n 
(%) 
Appropriate override, n 
(%) 
Insulin regular infusion (n=262) 0 262 (100) 
Calcium gluconate (n=56) 2 (3.6) 54 (96.4) 
Glycopyrrolate (n=79) 0 79 (100) 
Heparin (n=60) 0 60 (100) 
Lorazepam (n=70) 0 70 (100) 
Midazolam (n=52) 3 (5.8) 49 (94.2) 
Ceftazidime (n=45) 25 (55.6) 20 (44.4) 
Furosemide (n=45) 0 45 (100) 
Cefepime (n=52) 23 (44.2) 24 (55.8) 
Acetaminophen (n=44) 21 (47.7) 23 (52.3) 
Fentanyl (n=39) 0 39 (100) 
Haloperidol (n=31) 0 31 (100) 
Potassium chloride (n=27) 1 (3.7) 26 (96.3) 
Bumetanide (n=21) 1 (4.8) 20 (95.2) 
Acetylcysteine (n=18) 1 (5.6) 17 (94.4) 
Metronidazole (n=18) 4 (22.2) 14 (77.8) 
Diltiazem (n=17) 0 17 (100) 
Morphine (n=15) 0 15 (100) 
Citalopram (n=15) 0 15 (100) 
Sulfamethoxazole-trimethoprim (n=15) 1 (6.7) 14 (92.3) 
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Table 3. Details of ADEs found in study 
Medication, Dose, Alert Details Comments 
Cefepime  
- 2 g q12hr 
- Inappropriate override 
- Possible ADE 
- Serious ADE 
- Patient with acute kidney injury, not 
appropriately renally dosed per 
institutional guidelines 
- Per attending note, patient with altered 
mental status 
- Changed to piperacillin-tazobactam 
Alprazolam  
- 2 mg q8hr 
- Appropriate override 
- Definite ADE 
- Serious ADE 
- Home medication 
- Per nursing note, patient should only be 
dosed 1 mg due to lethargy after 2 mg 
dose, which increased patient risk of 
falling 
- Dose decreased to 1 mg 
Ceftazidime  
- 2 g q8hr 
- Appropriate override 
- Possible ADE 
- Serious ADE 
- Initiated for suspected ventilator-
associated pneumonia, resolving acute 
kidney injury 
- Per attending note, patient with altered 
mental status 
- Changed to piperacillin-tazobactam 
Citalopram  
- 40 mg daily 
- Appropriate override 
- Definite ADE 
- Serious ADE 
- Home medication 
- Per physician note, patient with 
somnolence 
- Decreased to 20 mg daily 
Glycopyrrolate 
- 0.2 mg IV q4hr PRN 
- Appropriate override 
- Possible ADE 
- Serious ADE 
- Initiated for secretion management 
- Altered mental status 
- Glycopyrrolate discontinued  
Haloperidol  
- 2-4 mg IV q4hr PRN 
- Appropriate override 
- Possible ADE 
- Significant ADE 
- Dose titrated from initial low-dose 
- Wife noted that medication made patient 
more agitated 
- Haloperidol discontinued 
Metoprolol  
- 20 mg IV q4hr; hold if SBP<90 or HR 
<60 
- Appropriate override 
- Definite ADE 
- Significant ADE 
- Metoprolol had been titrated to high dose, 
hold parameters present 
- Blood pressure to 74/45 after dose 
- Metoprolol discontinued 
Morphine  
- 60 mg q8hr 
- Appropriate override 
- Possible ADE 
- Serious ADE 
- Home medication 
- Auditory hallucinations; falls 
asleep/somnolent from morphine and 
lorazepam; unresponsive so morphine 
shut off 
- Morphine discontinued 
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Sulfamethoxazole-trimethoprim  
- 560 mg (trimethoprim) PO q8hr 
- Appropriate override 
- Definite ADE 
- Significant ADE 
- Treatment for Pneumocystis jiroveci 
pneumonia 
- Serum potassium increased to 6.3; no 
peaked T waves 
- Treated with sodium polystyrene, regular 
insulin/dextrose and calcium; 
- Sulfamethoxazole-trimethoprim 
discontinued 
Ziprasidone  
- 160 mg daily 
- Appropriate override 
- Possible ADE 
- Serious ADE 
- Home medication 
- Attending note mentioning QTc to 526 
(baseline <500 msec) 
Zolpidem  
- 10 mg nightly 
- Appropriate override 
- Possible ADE 
- Serious ADE 
- Home medication 
- Male patient 
- Nurse noted lethargy in the morning but 
more alert as day passed 
HR = heart rate; IV = intravenous; PO = by mouth; PRN = as needed; SBP = systolic blood pressure 
 
 
 
 
 
